GLP‑1 Receptor Agonist Safety and Clinical Decision‑Making
Gastrointestinal Safety Profile
- The 2025 BMJ clinical guidelines (moderate‑certainty evidence) list severe gastrointestinal events as a recognized harm across all risk categories for GLP‑1 receptor agonists. 1, 2, 3, 4
Cardiovascular and Kidney Benefit versus GI Risk
The 2025 BMJ guidelines (moderate‑to‑high certainty evidence) state that, in patients with moderate to high cardiovascular or kidney risk, the cumulative cardiovascular and renal benefits of GLP‑1 receptor agonists outweigh their gastrointestinal risks. 1, 2, 3
The Lancet Diabetes & Endocrinology recommendation (2021) advises using GLP‑1 receptor agonists when indicated for cardiovascular or kidney protection, noting that diverticular disease is not a contraindication. 5, 1
The 2025 BMJ guidelines (moderate certainty) advise that, for patients at lower cardiovascular/kidney risk, the limited cardiovascular benefit combined with persistent gastrointestinal risks makes most patients unlikely to accept GLP‑1 receptor agonist therapy. 6, 4
The 2025 BMJ guidelines (moderate certainty) highlight that patients with obesity who seek weight reduction may still consider GLP‑1 receptor agonists despite the gastrointestinal risk profile. 3
Managing Cumulative Gastrointestinal Burden
- The 2025 BMJ guidelines (moderate certainty) recommend avoiding additional gastrointestinal burden by considering alternative therapies in patients already receiving other GI‑affecting medications (e.g., metformin) when the combined risk outweighs expected benefits. 6
Guideline Recommendations for Baseline Laboratory Testing Prior to GLP‑1 Receptor Agonist Initiation
Required Baseline Laboratory Assessments
- The American Diabetes Association (2025) states that no specific baseline laboratory tests are mandated before initiating GLP‑1 receptor agonist therapy; decisions should be based on clinical criteria such as glycemic level, cardiovascular/kidney risk, and weight‑management goals. 7
Glycemic Monitoring
- Hemoglobin A1C should be measured to document baseline glycemic control and set treatment targets; when added to metformin, GLP‑1 receptor agonists typically reduce A1C by approximately 0.7–1.0 %. 7
Clinical Practice Considerations
- Therapeutic inertia must be avoided: clinicians should not postpone GLP‑1 receptor agonist initiation for extensive laboratory workup when patients have not achieved individualized glycemic goals. 7